Structural basis for assembly and disassembly of the IGF/IGFBP/ALS ternary complex.
Level 5 - mechanism / opinion, no new human data
In vitro structural biology (cryo-EM) and biochemical study without human clinical data.
PubMed 35907924 · doi:10.1038/s41467-022-32214-2
What was done
Researchers resolved the single-particle cryo-EM structure of the human insulin-like growth factor 1 (IGF1), IGF-binding protein 3 (IGFBP3), and acid-labile subunit (ALS) ternary complex. They also conducted in vitro biochemical assays to analyze how proteolysis of the central linker domain of IGFBP3 affects complex disassembly and IGF1 release.
What was found
The cryo-EM structure revealed a parachute-like architecture for the IGF1/IGFBP3/ALS ternary complex and identified structural determinants of its sequential assembly. In vitro biochemical assays demonstrated that cleavage at the IGFBP3 central linker domain leads to the shedding of its C-terminal domain rather than immediate direct release of IGF1, producing an intermediate complex that facilitates IGF1 bioavailability. The abstract reports no quantitative parameters, cryo-EM resolution values, or statistical metrics.
Why it matters
These findings delineate the molecular mechanics of how the circulating IGF reservoir is assembled and selectively dismantled to release active growth factor. This structural model provides a mechanistic basis for understanding growth disorders caused by mutations in IGF1 and IGFALS.
Limits
The study is restricted to in vitro structural and biochemical experiments with no in vivo animal or human clinical validation. The abstract does not report specific quantitative measurements, such as cryo-EM map resolution, binding affinities, or proteolysis reaction rates.
Cited by
- supports The half-life of insulin-like growth factor 1 (IGF-1) in serum is approximately 12 hours.